Intravascular Stenting and Angiographic Results: A randomized trial comparing paclitaxel-eluting balloon angioplasty plus stenting versus standard balloon angioplasty plus stenting versus directional atherectomy for symptomatic femoral artery disease - ISAR-STATH
Contribution To Literature:
The ISAR-STATH trial showed that paclitaxel-eluting balloon angioplasty plus stenting was superior to other endovascular strategies at preventing restenosis.
Description:
The goal of the trial was to evaluate three endovascular strategies for treating symptomatic superficial femoral artery disease.
Study Design
- Randomized
- Parallel
Patients with symptomatic superficial femoral artery disease were randomized to paclitaxel-eluting balloon angioplasty plus stenting (n = 48) versus plain balloon angioplasty plus stenting (n = 52) versus directional atherectomy with distal protection and bailout stenting (n = 55).
Inclusion criteria:
- Patients with claudication and >70% stenosis or occlusion of the superficial femoral artery
- Total number of enrollees: 155
- Duration of follow-up: 24 months
- Mean patient age: 71 years
- Percentage female: 31%
- Percentage with diabetes: 33%
Exclusion criteria:
- Acute ischemia of the superficial femoral artery
- Untreated ipsilateral iliac stenosis >70%
- Previous stenting of the superficial femoral artery
- Popliteal stenosis >70%
- Severe renal insufficiency
- Limited life expectancy
Principal Findings:
The primary outcome, percent diameter stenosis at 6 months, occurred in 34% of the paclitaxel-eluting balloon angioplasty plus stenting group and 56% of the plain balloon angioplasty plus stenting group versus 55% of the directional atherectomy with distal protection and bailout stenting group (p = 0.009 for paclitaxel-eluting balloon plus stent versus plain balloon angioplasty plus stent group and p = 0.007 for paclitaxel-eluting balloon plus stent versus directional atherectomy group).
The secondary outcome, target lesion revascularization, was 17% for paclitaxel-eluting balloon plus stent, 37% for plain balloon angioplasty plus stent group, and 53% for directional atherectomy plus bailout stent group (p = 0.017 for paclitaxel-eluting balloon versus other groups).
Interpretation:
Among patients with symptomatic superficial femoral artery disease, paclitaxel-eluting balloon angioplasty plus stenting appeared to be superior to plain balloon angioplasty plus stenting or to directional atherectomy with distal embolic protection plus bailout stenting. Paclitaxel-eluting balloon angioplasty plus stenting was associated with the lowest percent diameter stenosis at 6 months (primary outcome) and the lowest incidence of target lesion revascularization at 24 months (secondary outcome).
References:
Ott I, Cassese S, Groha P, et al. Randomized Comparison of Paclitaxel-Eluting Balloon Angioplasty Plus Stenting Versus Standard Balloon Angioplasty Plus Stenting Versus Directional Atherectomy for Symptomatic Femoral Artery Disease (ISAR-STATH). Circulation 2017;Apr 19:[Epub ahead of print].
Keywords: Angioplasty, Balloon, Angioplasty, Balloon, Coronary, Atherectomy, Constriction, Pathologic, Coronary Occlusion, Diabetes Mellitus, Endovascular Procedures, Femoral Artery, Intermittent Claudication, Myocardial Revascularization, Paclitaxel, Stents, Secondary Prevention, Vascular Diseases
< Back to Listings